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Whey protein supplementation, containing large amount of leucine, has been a 
traditional intervention to maintain net protein balance in the past decades. It has been 
recognized that leucine alone is able to stimulate protein synthesis by activating mTOR 
and its related downstream pathway without affecting protein degradation, whereas its 
metabolite β-hydroxy-β-methylbutyrate (HMB) is known to attenuate protein degradation 
when provided chronically. However, the mechanism of HMB’s benefit remains unclear.  
To address how HMB regulates protein synthesis and degradation signaling pathways, we 
compared one dose of whey protein (187.5mg/kg), HMB (400mg/kg) or leucine (1.4g/kg) 
by oral gavage. Blood was collected at 0, 45 and 90 min for blood glucose and plasma 
insulin analysis. Red and white gastrocnemius muscle was taken separately 90 min after 
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gavage. Blood glucose was reduced by leucine at 45 and 90 min post gavage. Plasma 
insulin was enhanced by leucine at 45 min and then decreased at 90 min post gavage, 
whereas HMB decreased plasma insulin through 90 min post gavege. Western blot 
analysis showed that HMB phosphorylated Akt in red gastronemius, and enhanced 
phosphorylation of mTOR in both types of muscles. Leucine phosphorylated mTOR, 
p70s6k and 4E-BP1 in both red and white gastronemius. Regarding protein degradation 
signals, phosphorylation of FOXO3A was enhanced by HMB, but not in the other 
treatment groups. Whey protein had no effect on those cellular signaling. Our results 
indicate that both HMB and leucine may stimulate protein synthesis through the mTOR 
pathway in red and white gastrocnemius muscles by different degrees with leucine more 
effective than HMB. HMB may have a greater effect than leucine on limiting protein 
degradation by phosphorylating Akt and FOXO3A in red and white gastrocnemius 
muscles. A combination of HMB and leucine, as a new interventional strategy, is 
predicted to maximize protein accretion by increasing protein synthesis as well as 
inhibiting protein degradation.  
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Greater attention to muscle mass loss has occurred in the past decades, due to 
related decreases in muscle power, strength, and quality of life. In humans, muscle loss 
starts to occur at 25-30 years old and there is ~10% muscle loss by 50 years of age. With 
aging, muscle loss can reach up to ~30% after 50 years of age (Hurley 1995). This 
atrophy occurs mainly in Type II fibers, especially in Type IIb muscle fiber.  
Whey protein supplementation is a common strategy to increase protein synthesis, 
because it provides a good balance of essential amino acids as substrate (Houston et al. 
2008). Also, whey protein can stimulate insulin secretion, which activates the mTOR 
pathway to increase protein synthesis (Tremblay and Marette 2001). Even though amino 
acids stimulate protein synthesis, not all amino acids can activate protein synthesis 
signaling pathways to the same degree. Leucine, as a significant branch-chain amino 
acid, has been shown to attenuate skeletal muscle atrophy through stimulating protein 
synthesis (Zanchi, Nicastro and Lancha 2008), via phosphorylation of mTOR and its 
downstream factors, p70s6k and 4E-BP1 (Anthony et al. 2000). β-hydroxy-β-
methylbutyrate (HMB), the metabolite of leucine, has also been reported to prevent 
skeletal muscle atrophy, but this appears to be done by decreasing protein degradation 
(Holecek et al. 2009).  
However, it is not clear how an acute supplement of HMB affects protein 
synthesis or degradation related signaling pathways, and whether HMB is more effective 
than leucine. Since HMB is the metabolite of leucine, we hypothesized that both HMB 
and leucine would affect protein synthesis and degradation signaling pathways, and HMB 
would have a better effect on blocking protein degradation compared to leucine or a whey 






  All of the animal research and procedures were approved by the Institutional 
Animal Care and Use Committee, at The University of Texas at Austin. Female Sprague-
Dawley rats (n=29) age 9-10 months were obtained from Charles River Laboratories 
(Wilmington, MA). They were housed 2 per cage in an animal room maintained at 21°C 
with a 12:12-h light-dark cycle. This reverse light cycle ensures that the rats are tested 
during their “waking” hours and fasted during their sleeping cycle. They were fed a 
standard laboratory diet (Prolab RMH 1800 5LL2, LabDiet, Brentwood, MO) and 
provided water ad libitum. The rats were allowed to acclimate for one week after arriving 
on campus. During the week of familiarization, each rat was periodically handled and 
gavaged using an empty syringe. After one week of acclimation and when rats weighed 
between 350-420g, they were randomly assigned into 4 treatment groups.  
EXPERIMENTAL DESIGN   
Following a 12-14h fast, rats were taken to the experimental room. Rats were 
wrapped in a towel and the end of their tails cut with a razor blade. The first drop of 
blood was discarded. The second drop of blood was used to measure blood glucose using 
a portable glucose analyzer (One Touch Ultra 2; LifeScan Inc., Milpitas, CA) at 0, 45, 
and 90 min. We collected another 500µl blood into a 1.5ml test tube containing 0.1ml 
EDTA (24mg/ml, pH 7.4) at each time point and put the tube on ice. Right after taking 
blood at 0 min, rats were intubated with one of four solutions.  
The treatment solutions consist of 1) control: Krebs-Henseleit Buffer (KHB); 2) 
whey protein (WP): 187.5mg/kg body weight; 3) HMB: 400mg/kg body weight; 4) 
Leucine: 1.4g/kg body weight. KHB was mixed by 10 x KHB stock I and II at pH 7.4. 
All rats were fed 10 ml/kg. Based on previous recommendations, whey protein was given 
as 187.5 mg/kg prepared as 18g/L in 50 ml KHB; HMB was given as 400 mg/kg 
prepared as 3g CaHMB·H2O in 50 ml KHB (Pimentel et al. 2011); leucine was given 1.4 
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g/kg prepared as 7g in 50 ml KHB (Anthony et al. 2000). All the supplementations were 
supplied by Abbott Laboratory (Abbott Nutrition, Columbus, OH) 
Immediately after taking blood at 90min, rats were anesthetized with an 
intraperitoneal injection of sodium pentobarbital (75 mg/kg of body weight) at which 
time red and white gastrocnemius were excised, frozen clamped in liquid nitrogen, and 
stored at -80°C for later analysis. Rats were then euthanized by cardiac injection of 
sodium pentobarbital (65 mg/kg body weight).   
 
PLASMA INSULIN ANALYSES 
Blood samples maintained on ice were centrifuged at 3000g for 10 min at 4°C and 
then the supernatant aliquoted to several test tubes and stored at -80°C for insulin 
analysis. All samples were tested in duplicate. Plasma insulin was measured using a 
radioimmunoassay kit (Linco Research, St. Charles, MO) with CV<10%. The 
125
I-labeled 
insulin was added into glass tubes containing standards, controls, and plasma samples. 
Rat insulin antibody was then added into the tubes. All tubes were incubated at 4°C 
overnight (20-24 hours). During that time, 
125
I-labeled and unlabeled insulin compete 
each other to bind to the antibody. The next day, the antigen-antibody complex was 
precipitated by adding precipitating solution, incubation, and spinning down. Then all 
tubes were counted in a gamma counter for 2mins. Standards were used to build up a 
standard curve.  
 
MUSCLE HOMOGENIZATION 
We weighed ~60µg red and white gastronemius separately and homogenized in 
ice-cold homogenization buffer (containing 20mM Hepes, 2mM EGTA50 mM NaF, 100 
mM KCl, 0.2 mM EDTA, 50 mM glycerophosphate, 1 mM DTT, 0.1 mM PMSF, 1 mM 
Benzamidine, 0.5 mM Na Vanadate) with a glass tissue grindle pestle (Corning Life 
Science, Acton, MA). Homogenates were centrifuged at 13,000g for 15 minutes at 4°C. 




A modified method of the Lowry Assay (Lowry et al. 1951) was used to 
determine muscle sample protein concentration. Copper-protein complex reaction occurs 
when copper is reduced. The copper-protein complex reduces Folin and Ciocalteu’s 
Phenol reagent, which produces a blue color that was measured by spectrophotometer at 
750nm. A standard curve (protein concentration versus absorption) was then produced 
and a linear regression formed. The protein concentration of each sample was determined 
from the linear regression equation. 
WESTERN BLOT 
Signaling proteins, including Akt/PKB, mTOR, p70s6k, 4E-BP1, FOXO3A and 
α-tubulin, were determined by Western Blotting. Sample proteins (100µg) was combined 
with an equal amount (1:1) of sample buffer (1.25M tris, 20% glycerol, 20% SDS, 0.25% 
bromophenol, β-mercaptoethanol, pH 6.8) and boiled at 95°C for 10 min. Then, equal 
amounts of muscle proteins (60-100µg) were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) using 10% gels for 80 min at 130V. The resolved proteins 
were transferred onto a nitrocellulose membrane (NC) using a wet transfer unit for 2 h at 
90V. The NC was then blocked in freshly prepared 7% non-fat dry milk in Tris-buffered 
saline (TBS) with 0.06% Tween20 (TTBS-MLK) for 20 minutes at room temperature 
with shaking. The blocked NC was then incubated with either affinity purified anti-
phospho-Akt/PKB (ser473), anti-phospho-mTOR (ser2448), anti-phospho-p70s6k 
(thr389), anti-phospho-4E-BP1 (thr37/46), anti-phospho-FOXO3A (ser318/321), or anti-
α-tubulin (Cell Signaling Technology, Inc., Danvers, MA) overnight at 4°C. The primary 
antibodies were diluted to either 1:800 (phospho-Akt/PKB, phospho-mTOR, phospho-
p70s6k, α-tubulin) or 1:650 (phospho-4E-BP1, phospho-FOXO3A) with freshly prepared 
TTBS-MLK. The next day, the NC membrane was washed 5min x 3 times with TTBS-
MLK which is followed by incubation for 1h at room temperature with species-specific 
(anti-rabbit) immunoglobulin G (IgG) secondary antibodies (Cell Signaling Technology, 
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Inc., Danvers, MA). The secondary antibodies were diluted to 1:800 in TTBS containing 
2% NFDM. After 3 additional 5 min washes, the NC membrane was visualized by 
Western Lightning Plus-enhanced chemi-luminescense (ECL) in accordance to the 
manufacturer’s instructions (Perkin Elmer Inc., Waltham, MA). Signaling Protein blots 
were quantified by a ChemDoc ECL detection system and Quantity One software (both 




A one-way ANOVA was performed on all muscle sample data. Blood glucose 
and plasma insulin data was performed using a two-way repeated ANOVA. Significance 
was considered at p<0.05. All statistical analyses were completed using PASW v19.0 
software (PASW Inc., Chicago, IL) and all values expressed as means ± standard error 














RESULTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Animal Characteristics 
There were no differences in average body weight among the different treatment 
groups Control (CTRL) 381.0 ± 4.8g; Whey Protein (WP) 388.3 ± 7.3g; HMB 387.1 ± 
10.9g; Leucine (LEU) 379.6 ± 11.6g. 
 
Blood glucose level 
Blood glucose concentration was determined following a 14 h fast and at 45 and 
90 min after one treatment dose. As shown in Fig. 1, there were no differences in fasting 
glucose among treatment groups. There were small changes in the blood glucose 
response for CTRL, WP, and HMB through 90 min; however, blood glucose was 
significantly decreased at 45 and 90 min for LEU supplementation compared to CTRL, 
WP, and HMB (Fig. 1A). The glucose area under the curve (AUC) was also lower for 
LEU relative to the other treatment groups (Fig. 1B). There were no differences in 
glucose AUC among the other treatment groups. 
 
Plasma insulin level 
Plasma insulin was increased at 45 min post leucine supplementation, but had 
returned to baseline by 90 min. HMB reduced plasma insulin at 45 min post treatment 
compared to the fasting insulin level. There were no significant differences among 
treatments at each time point (Fig. 2A). Insulin AUC was significantly increased with the 




was phosphorylated by HMB in red gastrocnemius muscle 
Akt/PKB protein phosphorylation at site ser473 was significantly increased 90 
min post HMB supplementation compared to WP and CTRL in red gastrocnemius 
muscle, but not in white gastrocnemius. There were no significant differences among the 





 was phosphorylated by both HMB and Leucine in red and white 
gastrocnemius muscle   
mTOR protein phosphorylation at site ser2448 was significantly increased 90 min 
post HMB supplementation compared to CTRL and WP in red gastrocnemius (Figure 
4A). mTOR
 ser2448 
phosphorylation was further enhanced with the LEU treatment in red 
gastrocnemius compared to HMB (Figure 4A). In white gastrocnumius, both HMB and 
LEU phosphorylated mTOR compared to CTRL and WP, but there was no significant 




was phosphorylated by Leucine in red and white gastrocnemius muscle 
p70s6k phosphorylation at site thr389 was significantly increased for LEU 
supplementation compared to all other treatments in both red and white gastrocnemius 
(Figure 5A and B). p70s6k phosphorylation had a tendency to be increased by HMB in 




 was phosphorylated by Leucine in red and white gastrocnemius 
muscle 
4E-BP1 phosphorylation at site thr37/46 was significantly increased 90 min post 
LEU compared with HMB, WP and CTRL in red and white gastrocnemius muscle. There 




 was phosphorylated by HMB in red and white gastrocnemius 
muscle 
FOXO3A protein phosphorylation at site ser318/321 was significantly increased 
for HMB compared with WP and CTRL both in red and white gastrocnemius muscle 
(Figure 7A and B). In addition, phosphorylation of FOXO3A was also higher with HMB 
treatment compared to LEU in white gastrocnemius muscle (Figure 7B). There was no 




Abundance of alpha tubulin was the same for all treatments. 
We probed our membranes with an antibody that detects endogenous levels of 
total alpha-tubulin protein. No statistical differences were detected between the treatment 
groups (Fig. 8A and B). This suggests that equal amounts of protein were loaded for all 
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  Figure 1. (A) Blood glucose after 14 h fast, and 45 and 90 min post supplementation. Values 
are means ± SE.  *, p<0.05 LEU vs. all other treatments at the same time point. #, p<0.05 
LEU at 45 and 90min vs. 0min. (B) Blood glucose AUC. Values are means ± SE.  Means 
with different letters are significantly different from each other (P <0.05). 
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               B 
               
                
Figure 2. (A) Plasma insulin after 14 h fast, and 45 and 90 min post supplementations. *, 
p<0.05 HMB at 45 vs. 0min. # p<0.05 LEU at 45 min vs. 0 and 90 min. (B) Plasma 
insulin AUC. Values are means ± SE.  Means with different letters are significantly 
different from each other (P <0.05). 
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Figure 3. (A) Red gastrocnemius and (B) white gastrocnemius Akt Ser-473 
phosphorylation 90 min after each treatment. Values are means ±SE. Means with 
different letters are significantly different from each other (P <0.05). 
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Figure 4. (A) Red gastrocnemius and (B) white gastrocnemius mTOR ser2448 
phosphorylation 90 min after each treatment. Values are means ±SE. Means with 
different letters are significantly different from each other (P <0.05). 
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Figure 5. (A) Red gastrocnemius and (B) white gastrocnemius p70s6k-thr389 
phosphorylation 90 min after each treatment. Values are means ±SE. Means with 
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             B 
           
 
Figure 6. (A) Red gastrocnemius and (B) white gastrocnemius 4E-BP1-thr37/46 
phosphorylation 90 min after each treatment. Values are means ±SE. Means with 
different letters are significantly different from each other (P <0.05) 
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Figure 7. (A) Red gastrocnemius and (B) white gastrocnemius FOXO3A-ser318/321 
phosphorylation 90 min after each treatment. Values are means ±SE. Means with 
different letters are significantly different from each other (P <0.05). 
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Figure 8. Total protein abundance of alpha-tubulin in red and white gastrocnemius muscles 
was used to evaluate the amount of protein equally loaded. Values are expressed as means 




The primary finding of the present study is that acute treatment of both HMB and 
leucine were able to partly increase cell signaling responsible for mRNA translation 
initiation to different degrees. Leucine appeared to be more effective in controlling 
protein synthetic signals; whereas HMB appeared to have a greater effectiveness limiting 
protein degradation as it caused a greater phosphorylation of FOXO3A. These findings 
implies that administered together they may have the capacity of stimulating protein 
synthesis and inhibiting protein degradation thus maximizing protein accretion. 
Greater attention has been paid to loss of muscle mass in recent decades due to 
related decreases in muscle function and quality of life. Different intervention strategies 
are recommended to prevent protein degradation or stimulate protein synthesis to 
enhance protein accretion. As described by previous studies, the insulin-dependent 
signaling pathway predominates protein synthesis both in animals and humans (Baar and 
Esser 1999, Terzis et al. 2008). Insulin is able to phosphorylate Akt/PKB through 
activation of PI3K. Once phosphorylated, Akt can phosphorylate and thus activate 
mTOR. Activated mTOR is then able to enhance phosphorylation of p70s6k and 4E-BP1 
(Dennis, Fumagalli and Thomas 1999). Multi-site phosphorylation of 4E-BP1 will 
dissociate from eIF-4E which allows it to form eIF4F by binding to eIF4G (Wang and 
Proud 2006). eIF4F is a central factor in the active ribosome. Therefore, phosphorylation 
of 4E-BP1 plays an important role in ribosome activation. In addition, phosphorylation of 
p70s6k by mTOR results in activation of rpS6, which is related to translation of mRNA 
and elongation factors (Roux et al. 2007). Also, p70s6k can phosphorylate glycogen 
synthesis kinase-3 which then inhibits eIF2B to increase mRNA translation. Both of these 
sub-branched pathways from mTOR ultimately increase the capacity of protein synthesis. 
Akt/PKB also plays an important role in regulation of protein degradation. Its 
downstream protein, forkhead box O (FOXO) 3A has been shown to promote atrophy in 
skeletal muscle (Sandri et al. 2004). FOXO3A is a transcription factor in the nucleus, 
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which can enhance E3 ligases such as atrogin-1 protein expression (Zanchi et al. 2010). 
Such enzymes are involved in the activity of the proteasome pathway, which then results 
in proteolysis. FOXO3A can be inhibited by phosphorylation at sites thr318/321 by Akt.  
With regard to protein synthesis, our current study observed that leucine treatment 
resulted in the phosphorylation of mTOR and its downstream proteins p70s6k and 4E-
BP1 in both red and white gastrocnemius muscle. These results suggest that leucine is 
able to stimulate protein synthesis through activating the mTOR pathway. The evidence 
for leucine activating mTOR directly in the absence of insulin has been previously 
reported (Byfield, Murray and Backer 2005, Nobukuni et al. 2005). Moreover, these 
studies also reported phosphorylation of mTOR by leucine results in the activation of 
p70s6k and inhibition of 4E-BP1 (Anthony et al. 2000, Byfield et al. 2005), which is 
consistent with our findings. However, we cannot eliminate the possibility that leucine 
activated the mTOR pathway in part through an insulin-dependent pathway. Therefore, 
we investigated the phosphorylation status of Akt/PKB. We found that phosphorylation 
of Akt/PKB was not stimulated by leucine in either muscle fiber types, which agrees with 
the findings of Liu et al. (Liu et al. 2002). Since Akt phosphorylation was not increased 
and the increase in plasma insulin was marginal following the leucine treatment, we 
conclude that leucine stimulates mTOR through an insulin-independent process.  
HMB, as the metabolite of leucine, has been shown to slow the biological 
decrease in muscle mass and strength in elderly individuals (Vukovich, Stubbs and 
Bohlken 2001). It is worth noting that there are no adverse reactions reported by subjects 
consuming HMB (Vukovich et al. 2001), whereas high amounts of leucine intake have 
been reported to have some side effects such as hypoglycemia (Digeorge, Auerbach and 
Mabry 1963). Moreover, it has been suggested that leucine’s activation of protein 
synthesis may be due to its conversion to HMB (Wilson, Wilson and Manninen 2008). 
We therefore investigated the effect of HMB on the intracellular signaling pathways 
controlling protein synthesis and degradation. It was demonstrated that HMB increased 
Akt/PKB phosphorylation in red gastrocnemius, but not in white gastrocnemius. Similar 
results were reported by Kornasio et al. (Kornasio et al. 2009). In contrast, Pimentel et al. 
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(Pimentel et al. 2011) found that the chronic treatment of HMB did not affect 
phosphorylation of Akt in the extensor digitorum longus (EDL) muscle of rats. These 
different findings are most likely due to differences in sampling of muscle. In their 
research, Pimentel et al. tested Akt signaling 15-18 hours after HMB oral gavage. It is 
highly unlikely that Akt would not remain phosphorylated for this length of time. In 
addition, Norton et al. has shown that most insulin-related signaling responses occur 
shortly after treatment gavage, usually within 1-3h (Norton et al. 2009). The mechanism 
by which HMB phosphorylates Akt is unknown. It is unlikely insulin was responsible for 
the increased phosphorylation of Akt, as insulin levels declined following HMB 
treatment. It is important to note, however, that other potent hormones are secreted in 
response to HMB that could influence the insulin signaling pathway. Insulin-like growth 
factor (IGF)-1α is another important hormone involved in muscle protein synthesis and it 
is capable of activating Akt/PKB (Skurk et al. 2005). One recent study reported that 
HMB increased serum IGF-1 concentration (Gerlinger-Romero et al. 2011). Therefore, it 
is suggested that HMB activated Akt/PKB through the IGF-1 pathway in the present 
study.  
Akt/PKB downstream proteins were also measured in the current study. We found 
that, relative to the control group, HMB increased phosphorylation of mTOR in both red 
and white gastrocnemius, but not to the same degree as leucine treatment. Furthermore, 
HMB did not increase the phosphorylation of 4E-BP1 or p70s6k relative to control in 
either red or white gastrocnemius. Eley et al. (Eley et al. 2007) found that HMB was able 
to promote phosphorylation of p70s6k and 4E-BP1. They also reported that 
hyperphosphorylation of 4E-BP1 increased association of eIF3E and eIF4G either with 
HMB alone or in combination with proteolysis-inducing factor (PIF), a catabolic signal 
(Eley et al. 2007). This discrepancy is likely related to differences in experimental 
models used. Eley et al (Eley et al. 2007) used murine myotubes in vitro with PIF to test 
the effect of HMB on the mTOR/p70s6k pathway. However, our in vivo model is more 
complicated, containing many factors that could affect the degree of phosphorylation 
such as secretion of hormone and the distribution of blood flow. Even though HMB did 
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not enhance phosphorylation of p70s6k and 4E-BP1 in our study, we still cannot rule out 
the possibility that HMB activates these proteins in in vivo, because these proteins were 
tested only at 90 min post gavage. However, it is unlikely HMB would have the same 
effect as leucine on protein synthesis, because mTOR was not activated by HMB to the 
same degree as by leucine.  
Based on our results, it appears that leucine has a strong capability to increase 
protein synthesis through activating the mTOR pathway, as previously noted (Pimentel et 
al. 2011, Anthony et al. 2000). HMB, however, did not appear to activate proteins critical 
for activation of protein synthesis. In addition, as mentioned above, leucine has been 
predicted to stimulate protein synthesis via HMB, because 60g leucine intake is believed 
to be metabolized into 3g HMB (Wilson et al. 2008). However, based on our results, it is 
unlikely that leucine’s stimulation of protein synthesis is due to its conversion to HMB.   
There is, however, strong evidence that HMB can block proteolysis in skeletal 
muscle due to aging, stress of exercise, AIDS, renal failure, and cancer (Smith, Mukerji 
and Tisdale 2005, Wilson et al. 2009, Wilson et al. 2008). Often these conditions involve 
progressive wasting of muscle, and a number of studies demonstrate the ability of HMB 
to prevent such muscle wasting. For example, Vulovich et al. (Vukovich et al. 2001) was 
able to increase fat-free mass in 70-year-old adults by providing HMB for 8 weeks. Smith 
et al. (Smith et al. 2005) was able to decrease proteasome-proteolysis activity in mice 
with tumor with a 9-day supplement of HMB and preserve the lean body mass of the 
mice. There are, however, few studies showing HMB’s effect on inhibition of protein 
degradation in normal sedentary models. Additionally, the underlying mechanism(s) by 
which HMB attenuates proteolysis still requires further investigation in vivo.  
In our current study, phosphorylation of FOXO3A was enhanced following HMB 
administration compared to control in red and white gastrocnemius. Our finding that 
HMB treatment resulted in phosphorylation of Akt in red gastronecmius and there was a 
trend for phosphorylation of white gastrocnemius suggests that Akt/PKB was responsible 
for phosphorylation of FOXO3A. Inhibited FOXO3A via its phosphorylation will block 
the enzymes involved in the proteasome and the ubiquitin pathways, and inhibit protein 
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degradation. Leucine, however, did not result in phosphorylation of FOXO3A, suggesting 
that leucine does not regulate protein degradation through the Akt/FOXO3A pathway 
similar to HMB. 
Our results also demonstrated that whey protein (187.5mg/kg) in the amount 
provided had no effect on plasma or muscle measurements. This finding is probably the 
result of an insufficient amount of protein provided to see an acute effect like 
demonstrated in other studies (Anthony et al. 2007, Morrison et al. 2008).  
In summary, our findings suggest that leucine was able to stimulate protein 
synthesis through the mTOR pathway. Although leucine was effective in stimulating 
protein synthesis, HMB appeared more able to inhibit protein degradation as indicated by 
its ability to phosphorylate FOXO3A. Therefore, the combination of leucine and HMB 
may be an optimal nutritional intervention to maintain net protein balance under 
conditions that increase proteolysis by increasing protein synthesis and reducing protein 
degradation without adverse health effects. Future research should evaluate the combined 
effects of leucine and HMB on protein synthesis and degradation and determine the 













Sarcopenia, characterized as loss of muscle mass, starts to occur after 25 years 
old. During aging, sarcopenia becomes more and more severe, especially in the type IIb 
muscle fiber type. It has been reported that loss of skeletal muscle mass is due to multiple 
reasons, including degenerated enzymatic activity, reduced capacity of hormone 
regulation, etc., which then cause increased protein degradation and decreased protein 
synthesis  (Orgel 1963, Lecker et al. 1999, Squier 2001). Current intervention is focusing 
on reversing decreased protein synthesis as well as preventing gradual protein 
degradation.  
One common strategy to maintain muscle mass in aged individuals is to consume 
high amounts of protein.  Protein, as a source of amino acids for muscle protein 
synthesis, is a strong stimulator of pancreatic insulin release. Both protein and insulin 
play critical roles in muscle protein synthesis by activating the mTOR pathway 
(Tremblay and Marette 2001). Whey, casein, and soy are three popular protein sources in 
dairy products. Whey and casein have been recognized as high quality proteins due to 
their high branched-chain amino acids components, especially leucine. Compared to 
casein, whey protein is digested faster and has been found to produce a better muscle 
protein synthetic response in older people (Phillips, Tang and Moore 2009, Dangin et al. 
2003). However, high amounts of protein consumption may have side-effects in elderly, 
such as an increase in kidney burden.  
Another strategy is giving leucine alone. Leucine has been found to activate 
mTOR and its downstream proteins. This benefit has been attributed to the conversion of 
leucine to its metabolite β-hydroxy-β-methylbutyrate (HMB) (Hider, Fern and London 
1969, Caperuto et al. 2007). HMB has been previously demonstrated to attenuate 
sarcopenia and decelerate the biological decrease in muscle strength in elderly 
individuals (Vukovich et al. 2001). Nevertheless, the mechanisms involved in prevention 
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of sarcopenia and how HMB stimulates protein accretion have not been described clearly. 
Moreover, most studies with HMB supplementation are chronic and focus on conditions 
resulting in rapid muscle loss, such as patients with cancer, excess stress, and ADIS. 
There are few reports about HMB treatment in normal (healthy and sedentary) situation 
or the age that protein starts to degrade.   
THE COMPOSITION OF MUSCLE FIBER TYPES 
Skeletal muscle is composed of distinct types of fibers that differ in their capillary 
density, enzymes, and metabolism. The major forms of muscle fiber types are classified 
as Type I fiber fibers (slow-twitch motor units) and Type II fiber (fast-twitch motor units) 
based on myosin heavy chain expression. Type II fibers are further subclassified into 
Type lla and Type llb fibers. Type I fibers contain more mitochondria, blood vessels and 
high myoglobin levels, etc. Therefore, Type I fibers are responsible for posture and 
oxidative exercise (Pette and Spamer 1986). Conversely, Type IIb fibers have stronger 
contraction capability and are responsible for power and strength. Type IIa is the 
intermediate between Type I and Type IIb fibers. Individual muscles are a mixture of 3 
types of muscle fibers, but their proportions vary based on different muscle actions. For 
example, the soleus is composed of Type I muscle fiber. Gastrocnemius and quadriceps 
are the mixture of Type IIa and Type IIb. Extensor digitorum longus (EDL) has much 
more Type llb. There are many intrinsic and extrinsic factors affecting muscle fiber 
changes such as gender, age, hormones, physical activities, etc. Aging is associated with 
the reduction of enzymes involved in energy metabolism, especially in the levels of the 
enzymes of the glycolytic pathway (Bass, Gutmann and Hanzlikova 1975). Some studies 
have shown decreased capacity to oxidize substrate through reductions in mitochondrial 
enzyme (Beyer et al. 1984, Cartee and Farrar 1987), but not in others (Young, Chen and 
Holloszy 1983, Bass et al. 1975). Therefore, the degree of muscle atrophy differs in 
various muscles dependent on fiber types, and aging has a negative impact on muscle 
function, especially power and strength. Type II fibers have been reported to lose more 
size (atrophy) than Type I fibers with aging (Lexell 1995). Such a selective denervation 
 24 
of Type II fibers within aging indicates the different functions in different fiber types and 
may also suggest different degree of regenerations between fiber types with treatments. In 
addition, it is not clear whether both Type IIa and Type IIb undergo protein degradation 
and muscle atrophy at the same level.   
 
PROTEIN METABOLISM AND ITS RELATED CELL-SIGNALING PATHWAY IN CONTROLLING 
MRNA TRANSLATION 
Protein content is dependent upon the rate of protein synthesis and the rate of 
protein degradation. A positive net protein balance occurs when protein is synthesized in 
excess of degradation, whereas a negative net protein balance occurs when the 
breakdown of proteins exceeds synthesis. Insulin has the capacity to increase protein 
synthesis by activating the mammalian target of rapamycin (mTOR) pathway, which is a 
key regulator in controlling protein synthesis both in human and animal studies (Baar and 
Esser 1999, Terzis et al. 2008). Rapamycin, the specific inhibitor of mTOR, was used to 
inhibit muscle hypertrophy in rodents, which further demonstrates the important role of 
mTOR in protein synthesis control (Bodine et al. 2001). Insulin first binds to the α-
subunit of the insulin receptor (IR) on the extracellular side of plasma membrane, which 
causes autophosphorylation of the β-subunit of the receptor. Then, pleckstrin homology 
(PH) domain on insulin receptor substrate (IRS)-1 binds to the activated IR to trigger Src 
homology 2 (SH2) domain on another downstream targets bound to IRS, such as 
phosphoinositide 3-kinase (PI3K) . PI3K has two subunits and with conformational 
change p85 subunit activates the catalytic subunit p110 domain. This in turn converts 
phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate 
(PIP3) on the intracellular side of plasma membrane. PIP3 recruits the PH domain 
containing protein, such as PDK1, Akt, and aPKC. Akt phosphorylates mTOR, which 
then phosphorylates its downstream factors: eukaryotic initiation factor 4E binding 
protein-1 (4E-BP1) and ribosomal protein S6 kinase  (p70S6K) (Dennis et al. 1999). 
Eukaryotic initiation factor 4E (eIF-4E) is necessary for activating mRNA translation 
initiation. Hyperphosphorylation of 4E-BP1 will cause it to unbind to eIF-4E and allow 
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eIF-4E to bind to eIF4G to start formation of eIF4F (Wang and Proud 2006). The latter is 
the central factor in the active ribosome. On the other hand, phosphorylation of p70s6K 
by mTOR leads to activation of ribosomal protein S6 (rpS6), which results in translation 
of specific mRNA for ribosomal proteins, elongation factors, and binding proteins (Roux 
et al. 2007). Both sub-branched pathways from mTOR ultimately increase the capability 
for protein synthesis.   
Akt is not only playing an important role in protein synthesis via the mTOR 
pathway but is also important in inhibiting protein degradation through phosphorylation 
of akt-forkhead box O-class (FOXO-3A) (Brunet et al. 1999). It has been shown that 
FOXO3A mRNA expression is increased in muscle in the fasted state and some other 
muscle atrophy states, such as aging and cachexia (Giresi et al. 2005, Lecker et al. 2004). 
Furthermore, FOXO3A dephosphorylation is sufficient to induce atrophy in whole 
muscle (Sandri et al. 2004).  
 
AGE-RELATED LOSS OF MUSCLE MASS 
Elderly individuals have a marked loss of muscle mass, known as sarcopenia, 
resulting in decreasing muscle strength and functionality. In aging humans, there is a 10% 
loss of muscle mass from 25 to 50 years of age, and muscle loss can reach up to ~30% 
after 50 years old (Hurley 1995). Selective atrophy occurs more in Type II muscle fibers 
than Type I, and occurs more in old women than men (Petrella et al. 2005).  
Sarcopenia is a multifactor problem. One of the important mechanisms causing 
muscle loss in aging is the loss of effective neuro-innervations over time. It is known that 
contraction of skeletal muscle depends on a signal from a motor neuron. Each axon 
terminal of a motor neuron is attached to the synapse at a neuromuscular junction (NMJ). 
Age-related neuromuscular changes are associated with degeneration of NMJ, 
fragmentation of nerve terminals, and loss of motor neurons. This results in the 
denervation of myofibers and subsequent loss of muscle mass (Luff 1998).  
Hormonal changes during aging are another crucial factors causing loss of muscle 
 26 
mass. Testosterone is one of the primary hormones for enhancing muscle protein 
synthesis, muscle mass and strength. The gradual reduction of testosterone in men over 
60 years old causes loss of muscle protein, thereby leading to loss of muscle mass. 
However, unlike testosterone, the reduction of estradiol level in women during 
menopause does not affect muscle mass and muscle strength. Conversely, insulin-like 
growth factor (IGF)-1α is another important hormone involved in muscle protein 
synthesis. Nevertheless, the circulating and intramuscular IGF-1α levels are markedly 
reduced with aging (Petrella et al. 2006), suggesting that age-related muscle wasting is in 
part due to the deficiency of IGF-1α.  
Post absorptive protein balance between young and old people is not different 
(Volpi et al. 2001), but protein turnover after a meal decreases with age, resulting in net 
protein loss (Katsanos et al. 2006). Also, it has been demonstrated that the concentration 
of mTOR and p70S6K in skeletal muscle was lower in elderly individuals than in the 
young (Cuthbertson et al. 2005). Furthermore, phosphorylation of these kinases is blunted 
in the elderly relative to the young when given a certain amount of protein or amino acids 
(Cuthbertson et al. 2005). Because mTOR is the key signaling protein to mediate protein 
synthesis through the phosphorylation of 4E-BP1 (Gingras et al. 1999, Wang et al. 2005) 
and p70S6K (Dennis et al. 1999), these findings suggest that the efficiency of cellular 
machinery for protein synthesis is impaired in aged skeletal muscle. Collectively, it can 
be concluded that, during aging, these cellular and physiological impairments lead to 
gradual muscle wasting through increased protein degradation and/or attenuated protein 
synthesis. Therefore, the current theory of developing therapeutic intervention is focusing 
on decelerating or reversing age-related muscle wasting by re-activation of the muscle 
protein synthesis system and/or interruption of signaling pathways involved in muscle 
protein degradation.  
Numerous interventional strategies have been used to maintain protein net balance 
in elderly, such as exercise, nutritional supplementation, medical therapy, and so forth. 
Nevertheless, in some circumstances, older individuals are unable to move freely and 
exercise, so nutritional supplementation would be a better option to attenuate protein 
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degradation or stimulate protein synthesis. Dietary protein is a common supplement. It is 
acceptable to large populations, including the elderly, because of its palatability and 
lower cost compared to other nutritional supplementation. As mentioned above, protein 
degradation occurs since 25 years old. Interventional strategies to prevent muscle loss via 
increasing protein synthesis or/and decreasing protein degradation are also important 
beginning with young adults.  
 
EFFECT OF PROTEIN SUPPLEMENTATION ON MUSCLE PROTEIN SYNTHESIS 
Protein synthesis requires 20 amino acids for peptide bond formation. Recent 
studies suggest that high-protein dietary supplements are sufficient interventions for 
increasing muscle mass and strength in aging individuals, because protein provides a rich 
amount of amino acids as substrates for protein synthesis in the body (Houston et al. 
2008). In addition, protein intake can stimulate insulin secretion, a primary anabolic 
hormone in the body, which also can stimulate muscle protein synthesis through the 
mTOR pathway as mentioned above (Tremblay and Marette 2001). Whey, casein, and 
soy proteins are all natural proteins found in daily food. Both whey and casein proteins 
contain high portion of branched-chain amino acids (BCAAs), which are main resources 
responsible for protein synthesis. Casein protein appears more responsive to inhibition of 
protein degradation, while whey protein has a greater effect on promoting protein 
synthesis. Compared to casein, whey protein is digested faster, thus whey protein is 
considered to be the best protein source for older individuals to rapidly elevate 
circulatory amino acid levels (Dangin et al. 2002, Dangin et al. 2003). It also contains a 
high concentration of leucine, an important BCAA in the regulation of protein synthesis 
through mTOR pathway (Boirie et al. 1997). 
Muscle atrophy in the elderly, however, may not be attenuated by protein 
supplementation alone. The elderly have a decreased sensitivity and responsiveness of 
protein synthesis associated with lower phosphorylation of anabolic signaling pathways 
and decrements in mRNA expression (Cuthbertson et al. 2005). Moreover, a 
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recommendation in that amount of protein may lead to some side-effect such as impairing 
renal function. However, it has been formed that a moderate serving of protein with high 
doses of essential amino acids are capable of stimulating muscle protein synthesis to a 
similar extent in the elderly compared to the young (Paddon-Jones and Rasmussen 2009). 
Therefore, supplementation of small amounts of essential amino acids has been 
recommended to maintain protein net balance. 
 
EFFECT OF LEUCINE SUPPLEMENTATION ON MUSCLE PROTEIN SYNTHESIS 
Amino acids are able to stimulate protein synthesis, but not all AAs have the same 
effectiveness. Leucine has been proven as a therapeutic strategy in attenuation of skeletal 
muscle atrophy in both in vitro and in vivo studies. Leucine promotes protein synthesis 
without affecting protein degradation (Zanchi et al. 2008). It exerts an anabolic effect 
which is similar to the effect of insulin. Compared to protein supplementation, leucine 
costs more and is less palatable. It has been known that protein synthesis in the elderly is 
much lower than in the young. This anabolic resistance can be fully countered by 
increasing the portion of leucine in the diet (Katsanos et al. 2006). The importance of 
leucine in regulating protein metabolism has been demonstrated in both human and rats 
models.  
The mechanism for regulating protein synthesis between leucine and protein are 
partly different. Leucine alone does not stimulate the mTOR pathway via activating PI3K 
or its downstream target Akt, which are seen in the insulin and IGF-1α signaling pathway 
(Nobukuni et al. 2005). Thereby, leucine may not mainly stimulate insulin secretion. 
Instead, leucine stimulates protein synthesis in skeletal muscle via enhancing 4E-BP1 
phosphorylation and p70S6K activity, which are downstream factors in the mTOR 
pathway (Anthony et al. 2000). In vitro, essential amino acids can phosphorylate mTOR 
directly, then promote p70S6K to stimulate protein synthesis independent of insulin 
(Byfield et al. 2005). However, old individuals have a lower protein synthesis sensitivity 
compared to young adults when given the same amount of AA, especially leucine. 
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(Dardevet et al. 2000). Some studies show that this reduced anabolic response to AA with 
aging may be related to dysregulated mTOR and its downstream signaling. (Cuthbertson 
et al. 2005, Guillet et al. 2004). It also appears that given a sufficient amount of leucine 
may trigger protein synthesis to a similar rate in elderly compared to youth, which 
suggests that the elderly should take protein supplements with sufficient leucine. In 
chronic studies, leucine supplementation was able to promote protein synthesis both in 
skeletal muscle and adipose tissue in rats without affecting insulin and IGF-1 level in 
plasma. (Lynch et al. 2002) Nevertheless, large amounts of leucine intake have been 
reported to cause diarrhea and may also impact renal function over time in the elderly. 
Thus, high-quantities of leucine intake may not be optimal to maintain a high protein 
synthesis in old adults.    
Some studies also reported that leucine has little effect on anticatabolism. In 22-
month old rats, a single leucine (5%) supplement meal fully restored the defective 
postprandial inhibition of proteasome-dependent proteolysis (Combaret et al. 2005). In 
addition, giving leucine alone or with other amino acids also inhibits whole-body protein 
degradation in dogs (Frexes-Steed et al. 1992b). However, the concentration of leucine 
required to prevent proteolysis is 10-20 times more than the requirement for protein 
synthesis. As we know, β-hydroxy-β-methylbutyrate (HMB) is the metabolite of leucine 
and α-ketoisocaproate (KIC). In human metabolism, every 100g leucine intake could be 
metabolized into 5g HMB; hence, the evidence above suggests that leucine has its effect 
on proteolysis via its metabolite HMB. 
 
Β-HYDROXY-Β-METHYLBUTYRATE (HMB) 
β-hydroxy-β-methylbutyrate (HMB) is reported to increase lean body mass, 
especially in older people, patients with AIDS, renal failure and cancer. It is worth noting 
that there are no adverse reactions reported by subjects consuming HMB (Vukovich et al. 
2001). 
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1) Effect of HMB on protein degradation 
Elderly people show more proteolysis than the young in a fasted state (Volpi et al. 
2001). Several lines of evidence reveal that HMB is capable of blocking proteolysis in 
skeletal muscle. For example, a 9-day supplementation of HMB attenuates protein 
degradation and subsequently preserves lean body mass in mice with tumor via lowering 
proteasome-proteolytic activity (Smith et al. 2005). Additionally, HMB is also found to 
attenuate tumor necrosis factor-α-(TNF-α) and angiotensin II-induced muscle protein 
degradation through inactivation of ubiquitin-proteasome pathway (Eley, Russell and 
Tisdale 2008). Moreover, another study shows that HMB positively impacts protein 
metabolism by primarily inhibiting proteolysis rather than promoting protein synthesis 
(Holecek et al. 2009). Although the inhibitory effects of HMB on ubiquitin-proteasome 
pathway and protein degradation were only found in in vitro models and mice with 
tumors, these findings still raise the possibility for use of HMB to prevent muscle protein 
loss in older adults and even young adults. Based on the ability of HMB to inhibit 
proteolysis, it is likely that leucine’s anticatabolic effects on protein degradation in 
skeletal muscle may be attributed to its conversion to HMB.   
 
2) Effect of HMB on protein synthesis 
In addition to the protective effect of HMB on protein degradation, both human 
and animal studies have shown that leucine and α-ketoisocaproate (KIC) supplementation 
significantly enhances protein synthesis only in catabolic states with increased proteolysis 
(e.g. starvation or burn trauma) (Sapir et al. 1983, Sax, Talamini and Fischer 1986, 
Bruzzone et al. 1991, Frexes-Steed et al. 1992a), suggesting that these anti-catabolic 
properties of leucine and its metabolites appear to be effective in decelerating the loss of 
muscle mass during aging. As the metabolite of leucine and KIC, HMB can also activate 
muscle protein synthesis through the insulin-related signaling pathway (Eley et al. 2007). 
HMB treatment for one month is able to phosphorylate both mTOR and p70s6k to induce 
muscle hypertrophy in EDL (Pimentel et al. 2011), but the same results do not appear in 
the soleus muscle. In addition, HMB appears to enhance protein synthesis by increasing 
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intramuscular IGF-1 gene expression. Additionally, a current in vitro study also showed 
that HMB is capable of stimulating IGF-1 mRNA expression in human myoblasts 
(Kornasio et al. 2009). Overexpression of IGF-1 has been proved to prevent age-related 
myofiber atrophy through activation of the mTOR pathway (Musaro et al. 2001).    
Nevertheless, it has not been clear whether this enhancing effect of HMB on IGF-1 gene 
expression also exists in in vivo. Furthermore, there have been no investigations focusing 
on whether acute treatment of HMB could activate protein synthetic related cell signaling 
pathways in aged or young adult mammalian models. Thus, the underlying mechanism(s) 
by which HMB increases protein synthesis and attenuates proteolysis requires further 
investigation. 
Based on the positive effects of whey protein, leucine and its metabolite HMB on 
maintaining muscle protein balance when protein starts to degrade due to aging, we 
propose this project to detect the impact and the underlying mechanism(s) of these three 
treatments on protein synthesis and partial protein degradation pathways in young adult 
rats’ skeletal muscle.  
 
SUMMARY 
A number of reports have demonstrated that intake of whey protein or essential 
amino acids, especially leucine, can stimulate protein synthesis in skeletal muscle by 
either increasing insulin secretion from the pancreas or activating the mTOR pathway 
directly, which further phosphorylates p70s6k and 4E-BP1 to increase ribosomal 
assembly, translation initiation, and elongation. Older adults have a gradual increase in 
protein degradation and less protein synthesis, due to dysregulated protein synthetic 
signaling in skeletal muscle. Larger intakes of whey protein or leucine are recommended 
to keep positive net protein balance, but too much whey protein or leucine intake can lead 
to adverse effects in the elderly. HMB, a metabolite of leucine, has been reported to 
prevent protein degradation as well as stimulate protein synthesis in long-term treatment, 
and it does not appear to cause any side effect. However, acute treatment of HMB and its 
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mechanisms on protein synthesis and degradation in vivo have not been examined. 
Therefore, if our research is able to demonstrate that acute HMB treatment can have a 
greater effect on the protein synthesis signaling pathway than protein or leucine treatment, 
HMB would be an optimal nutritional intervention for prevention of muscle loss and 





















APPENDIX A- MUSCLE HOMOGENIZATION 
Muscle homogenization buffer (100ml, pH7.4) 
Reagent Concentration (mM) Amount (g) 
HEPES 20 0.477 
EGTA 2 0.076 
NaF 50 0.209 
KCl 100 0.746 
EDTA 0.2 0.0074 
β-Glycerophosphate 50 1.08 
DTT 1 0.015 
PMSF 0.1 0.00174 
Benzamidine 1 0.0157 
Soduim vanadate 0.5 0.0092 
Add reagents in order to 80ml ddH2O, adjust pH to 7.4, and bring the volume to 100ml 
with stirring on a magnetic plate. 
Homogenization procedure; 
1. Weigh approximately 70mg of muscle sample; 
2. Dilute muscle to 1:8 (wt/vol) in homogenization buffer; 
3. Homogenize muscle on ice (3 x 10sec strokes) with a glass tissue grinder pestle at 
3000rpm by an electrically-powered stirrer; 
4. Centrifuge muscle samples at 14,000g for 10 minutes at 4°C; 








APPENDIX B- WESTERN BLOT 
30% Acrylamide and 1% Bisacrylamide Mixture (200ml) 
Add 58g Acrylamide and 2g Bisacrylamide in order to 150ml ddH2O stirring on a 
magnetic plate and bring to 200ml volume with ddH2O. Filter this mixed solution through 
Whatman #1 filter paper and stored in a dark bottle due to the high light sensitivity at 
4°C. 
1.5M Tris, pH8.8 (500ml) 
Add 90.82g Trisbase to 400ml ddH2O stirring on a magnetic plate and bring to 500ml 
volume with ddH2O. Adjust pH to 8.8 with 12N and 1N HCl. Store it at 4°C. 
1.0M Tris, pH 6.8 (500ml) 
Add 60.57g Trisbase to 400ml ddH2O stirring on a magnetic plate and bring to 500ml 
volume with ddH2O. Adjust pH to 6.8 with 12N and 1N HCl. Store it at 4°C. 
10% SDS (100ml) 
Add 10g SDS to 80ml ddH2O stirring on a magnetic plate and bring to 100ml volume 
with ddH2O. Filter this solution through Whatman #1 filter paper. 
20% SDS (100ml) 
Add 20g SDS to 80ml ddH2O stirring on a magnetic plate and bring to 100ml volume 
with ddH2O. Filter this solution through Whatman #1 filter paper. 
10% APS (1ml) 
Add 0.1g APS to 1.5ml test tube with 1ml ddH2O and vortex until dissolve. Make fresh 
daily. 
10 x Running Buffer (2L) 




Add the reagents into 1.5L ddH2O stirring on a magnetic plate and bring to the volume 
with ddH2O 
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10x TTBS (2L, pH7.4) 
Reagent Amount 
TrisBase 24.2 g 
NaCl 175.36 g 
Tween 20 12 ml 
Add the reagents into 1.5L ddH2O stirring on magnetic plate and bring to the volume 
Ponceau S.  
Reagent Amount 
Dye-Ponceau S 0.05 g 
Acetic Acid 2.5ml 
Add the reagents into 50ml ddH2O and vortex until dissolve. Recycled to be used later. 






Add reagents in order into 1400ml ddH2O stirring on a magnetic plate. Bring the volume 
into 2L with ddH2O.  
0.25% Bromophenol Bule  
Add 0.0125g Bromophenol Bule into 5ml ddH2O 
Sample buffer (50ml) 
Reagent Amount 
1.25M Tris-HCl (Ph 6.8) 5ml 
Glycerol 10ml 
20% SDS 5ml 
Β-Mercaptoethanol 2.25ml 
0.25% Bromophenol Blue 1.6ml 
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Add reagents in the order listed to 20ml ddH2O stirring on a magnetic plate and bring to 




Western blot procedure 
1. Preparing resolving gel solution (10% resolving gel for 2 gels): 
Reagent Amount 
H2O 4 ml 
Acrylanide mix 3.3 ml 
1.5M Tris (pH 8.8) 2.5 ml 
20% SDS 0.1 ml 
10% APS 0.1 ml 
TEMED 0.004 ml 
Add all reagents above into 50ml test tube. Then mix them and fill ¾ full caster with a 
glass pipette. Overlay with 300ul butanol. Allow 1h for gel to polymerize. 
2. After gel polymerization, pour off butanol from the resolving gel and rinse between 
casting plates with ddH2O and dry it with KimWipes. 
3. Preparing stacking gel solution (for 2 gels) 
Reagent Amount 
H2O 3.4 ml 
Acrylanide mix 0.83 ml 
1.0M Tris (pH 6.8) 0.63 ml 
20% SDS 0.05 ml 
10% APS 0.05 ml 
TEMED 0.005 ml 
Add al reagents above into 15ml test tube. Then mix them and fill the caster with 
stacking gel solution then put combs into place. Allow 45 min for stacking gel to 
polymerize. 
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4. Preparing samples 
a. Take the samples our of -80°C and thaw them on ice 
b. Dilute samples 1:2 with sample buffer in labeled microcentrifuge tubes. 
c. Vortex and place in boiling water (~90-95°C) for 8min 
5. Preparing 1 x Running buffer 
Add 100ml 10x Running buffer into 900ml ddH2O stirring on a magnetic plate. 
6. After stacking gel has polymerized, carefully remove the combs and assemble gel 
apparatus. Fill inner chamber and out chamber with 1 x running buffer. 
7. Load 10 ul of standard, 12-20 ul of sample, or 8 ul of molecular weight marker to 
corresponded gel lane.  
8. Electrophresis at 170V for 1h. 
9. After the electorphoresis, prepare for wet-transfer buffer showed as above. 
10. Cut 9.5 x 6cm rectangle Nitric Cellular Membrane, label it, and place membrane in wet-
transfer buffer for 15min on a shaker. 
11. Carefully separate casing plates, cut off stacking gel and place resolving gel in wet-
transfer buffer for 15min on a shaker. 
12. Soak four of the spongy pads and filter paper (2 for each gel) in the wet-transfer buffer 
for a few minutes.  
13. Making the gel “sandwich” 
a. Place cassette in a container filled with transfer buffer. Black side down.  
From bottom to top, add a spongy pad, a filter paper, a gel, a NC membrane, another 
filter paper, another spongy pad. Roll out bubbles with wetted glass tube.  
b. Close cassette. Place in transfer apparatus. 
c. Add ice to the small container and place in transfer apparatus as well. 
d. Fill the transfer apparatus with transfer buffer and add the top piece with electrodes to the 
apparatus.  
e. Place transfer apparatus in a larger plastic container fill the large plastic container with 
ice. 
f. Electrophresis at 90V for 2h. 
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14. During the transfer, prepare 1 x TTBS. 
Add 100ml 10 x TTBS into 900ml ddH2O stirring on a magnetic plate. 
15. Prepare 7% non-fat dry milk (NFDM). 30ml per membrane. 
Add 4.2g NFDM into a 100ml beaker containing 60ml 1 x TTBS stirring on a magnetic 
plate.  
16. After the transfer, take out the “sandwich”. Stain each NC membrane with Ponceau S. for 
5 seconds and put membrane into 1 x TTBS on a shaker to wash out Ponceau S. on 
Membrane. 
17. Place NC membrane a container with 7% NFDM and block for 20min with gently 
agitation. 
18. During blocking, prepare antibody with 2% NFDM. 10ml per membrane 
Add 0.4g NFDM into 20ml 1 x TTBS stirring on a magnetic plate. Then add appreciate 
ratio of antibody into 2% NFDM 
19. After blocking the membrane, wash 3 x 5min in 25ml TTBS. 
20. Incubate membrane with the primary antibody overnight at 4 °C with gently agitation. 
21. After overnight incubation with the primary antibody, wash membrane 3 x 5min in 25 ml 
TTBS. 
22. Incubate membrane with species specific secondary antibody for 1h at room temperature 
with gently agitation. 
23. After incubation with the secondary antibody, wash membrane 3 x 5min in 25 ml TTBS. 
24. Visualize protein bands using an ECL detection kit and Bio-Rad ChemiDoc detection 
system according to the manufacturer’s instructions. 





APPENDIX C- LOWERY PROTEIN ASSAY  
      1. Thaw one aliquot of 5mg/ml bovine serum albumin (BSA) stock (-20°C)      
and serially dilute it with deionized water to generate a standard curve as follows:  
  
   Water (ml) Protein (ml) Protein Conc.(mg/ml) 
 Blank  1.0  0  0 
 A  1.8  0.2 of stock  0.5 
 B  0.2  0.8 of A  0.4 
 C  0.5  0.5 of B  0.2 
 D  0.5  0.5 of C  0.1 
 E  0.5  0.5 of D  0.05 
 F  0.5  0.5 of E  0.025 
  
Set up duplicate 12x75mm glass assay tubes of each standard  
 2.  Dilute samples with deionized water in 1:30 ratio. Keep on ice. Set up 
duplicate glass assay tubes for each sample  
 3.  Make Solution A: add 48 ml of sodium carbonate (20 g/l of 0.1 NaOH) to a 
125 ml Erlenmeyer flask. Gently layer 1 ml of 2% sodium potassium tartate over the 
surface of the sodium carbonate. Then gently layer 1 ml of 1% cupric sulfate over the 
sodium potassium tartate. Mix Solution A by swirling, then by vigorous vortexing  
 4. To the duplicate 12x75mm glass assay tubes, add 0.1 ml of standards or 
samples. Add 1.0 ml of Solution A to each tube. Next vortex each individual tube. 
Incubate tubes at room temperature for 10 minutes  
 5. Dilute phenol reagent 1:2 with deionized water. After the tubes have incubated 
for the 10 minutes, add 0.1 ml of the diluted phenol reagent into each glass tube while 
vortexing the glass tube. Incubate at room temperature for 30 minutes  
 6. Turn on the spectrophotometer and let the bulb warm up at a wavelength of 750 
nm. Once the 30 minutes incubation are over, blank the spectrophotometer with the 
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“blank” tube. Then read every sample. Use the standard curve to determine protein 



























APPENDIX D- RAT INSULIN ASSAY 
 Day one: 
1. Dilute all samples in half with assay buffer. 
2. Thaw all the solutions. Hydrate 125I-insulin with entire contents of Label Hydrating 
Buffer. Allow to sit at room temperature for 30mins, with occasional gentle mixing. 
3. Pipette 200ul of Assay Buffer to the Non-specific binding (NSB) tubes (3-4) and 100ul to 
reference tubes (5-6). No buffer is added to tubes 7 through the end of the assay. 
4. Pipette 100ul of standards and quality controls in duplilcate. 
5. Pipette 100ul of each sample in duplicate. 
6. Pipette 100ul of hydrated 125I-insulin to all tubes.  
7. Pipette 100ul of rat insulin antibody to all tubes except total count tubes (1-2) and NSB 
tubes (3-4). 
8. Vortex, cover, and incubate at 4°C overnight (20-24 hous) 
Day two: 
1. Add 1ml of cold precipitating reagent to all tubes except total count tubes (1-2) on ice. 
2. Vortex and incubate 20mins at 4°C 
3. Spin down all tubes except total count tubes (1-2) for 20mins at 3,000xg at 4°C. 
4. Immediately decant the supernatant of all tubes except total count tubes (1-2), drain tubes 
for 60 seconds, and then blot excess liquid from lip of tubes.  
5. Count all tubes in a gamma counter for 2mins and get the concentration based on the 








APPENDIX E- TREATMENTS SOLUTION PREPARATION  
1. Make 10 x Krebs-Henseleit Buffer (KHB) Stock 1 and 2 
KHB Stock 1 10x (500 ml)  
Chemical Concentration Amount (g) FW Catalog # 
NaCl 1.6 M 33.895 58.44 SX0420-3 
KCl 46 mM 1.715 74.56 P-217 
KH2PO4 11.6 mM 0.789 136.1 P-0662 
NaHCO3 253.0 mM 10.625 84.01 S-6014 
 
 KHB Stock 2 10x (500 ml)  
Chemical Concentration Amount (g) FW Catalog # 
CaCl2·2H2O 25 mM 1.8375 147 C-3881 
MgSO4·7H2O 4.46 mM 1.4295 246.48 M-1880 
 
2. Make 200 ml 1x KHB combining 20 ml of Stock 1 and 2 with 150 ml ddH2O, pH 
solution to 7.4 and then bring volume to 200 ml by adding more ddH2O.  
3. Making whey protein (WP) solution: 
Amino acids components per 100 g whey protein   













Add 937.5 mg WP in 25 ml KHB stirring on a magnetic plate and bring to 50ml volume 
with KHB. 
4. Making HMB solution: 
Add 3g CaHMB·H2O in 40 ml KHB stirring on a magnetic plate and bring to 50ml 
volume with KHB 
5. Making leucine solution: 
Add 7g leucine in 35 ml KHB stirring on a magnetic plate for 15 min and bring to 50ml 
volume with KHB, and then keep stirring on the magnetic plate at 50°C at least overnight 


















APPENDIX F- RAW DATA  
Blood glucose data 





 (mg/dl x90 
min) 
1 CTRL 89.5 81.0 82.5 -540.0 
6 CTRL 87.0 92.5 80.5 101.3 
11 CTRL 82.0 90.5 90.5 573.8 
13 CTRL 87.0 91.5 84.5 146.3 
18 CTRL 83.5 95.5 89.0 663.8 
23 CTRL 96.5 87.5 85.5 -652.5 
44 CTRL 106.0 102.5 88.5 -551.3 
2 WP 93.0 99.0 105.5 551.3 
7 WP 87.5 100.5 86.0 551.3 
12 WP 84.5 81.0 81.5 -225.0 
17 WP 96.5 91.0 91.0 -371.3 
22 WP 102.5 98.0 98.0 -303.8 
27 WP 91.0 88.0 87.0 -225.0 
32 HMB 90.0 89.5 90.5 -11.3 
33 HMB 107.0 106.5 100.0 -180.0 
34 HMB 82.0 89.0 90.0 495.0 
35 HMB 90.5 85.5 86.5 -315.0 
36 HMB 93.0 107.5 95.5 708.8 
37 HMB 76.5 67.5 78.0 -371.3 
39 HMB 95.0 101.0 96.5 303.8 
16 LEU 98.0 83.0 80.5 -1068.8 
21 LEU 91.5 81.5 89.0 -506.3 
26 LEU 82.5 76.5 67.5 -607.5 
40 LEU 106.0 80.0 71.0 -1957.5 
41 LEU 85.0 77.0 77.0 -540.0 
42 LEU 85.5 64.0 63.5 -1462.5 





Plasma insulin data 






AUC  (ng/ml 
x90 min) 
1 CTRL 1.622 0.908 1.020 -45.675 
6 CTRL 0.274 0.248 0.132 -4.365 
11 CTRL 0.322 0.498 0.352 8.595 
13 CTRL 0.338 0.342 0.384 1.215 
18 CTRL 0.388 0.470 0.512 6.480 
23 CTRL 0.636 0.344 0.276 -21.240 
44 CTRL 0.788 0.484 0.736 -14.850 
2 WP 0.296 0.384 0.352 5.220 
7 WP 0.688 0.510 0.418 -14.085 
12 WP 1.000 0.364 0.438 -41.265 
17 WP 0.522 0.404 0.514 -5.490 
22 WP 0.890 0.578 0.548 -21.735 
27 WP 0.444 0.314 0.370 -7.515 
32 HMB 0.880 0.290 0.356 -38.340 
33 HMB 2.760 1.506 1.210 -91.305 
34 HMB 0.164 0.022 0.038 -9.225 
35 HMB 0.298 0.270 0.242 -2.520 
36 HMB 0.922 0.346 0.558 -34.110 
37 HMB 0.234 0.026 0.100 -12.375 
39 HMB 0.956 0.822 0.708 -11.610 
16 LEU 0.380 0.670 0.292 11.070 
21 LEU 0.238 0.228 0.176 -1.845 
26 LEU 0.856 1.438 1.006 29.565 
40 LEU 0.260 0.398 0.404 9.450 
41 LEU 0.848 1.631 1.112 41.175 
42 LEU 0.428 0.976 0.688 30.510 







Western blotting data 
 











1 CTRL 0.337 0.160 0.083 0.409 0.720 0.900 
6 CTRL 0.270 0.600 0.056 0.257 0.670 1.026 
11 CTRL 0.112 0.320 0.060 0.940 0.996 0.869 
13 CTRL 0.142 0.603 0.088 0.908 1.142 0.936 
18 CTRL 0.135 0.564 0.034 0.836 1.255 1.094 
23 CTRL 0.148 0.459 0.090 1.047 1.029 0.908 
44 CTRL 0.129 0.100 0.046 0.305 1.050 0.720 
2 WP 0.148 0.296 0.026 0.320 0.890 0.949 
7 WP 0.150 0.265 0.074 0.753 0.640 0.932 
12 WP 0.114 0.337 0.089 0.565 1.132 0.939 
17 WP 0.301 0.493 0.027 0.833 1.364 0.996 
22 WP 0.168 0.452 0.067 0.823 0.891 0.831 
27 WP 0.136 0.516 0.030 0.659 0.685 0.722 
32 HMB 0.236 0.770 0.066 0.909 1.790 0.966 
33 HMB 0.539 0.436 0.151 0.883 1.202 0.726 
34 HMB 0.248 0.874 0.103 0.494 1.251 0.948 
35 HMB 0.231 0.590 0.040 0.887 1.494 0.923 
36 HMB 0.206 0.705 0.046 0.615 1.604 1.032 
37 HMB 0.152 0.592 0.080 0.655 1.224 0.953 
39 HMB 0.357 0.586 0.123 0.471 1.473 0.852 
16 LEU 0.131 1.178 0.230 1.470 1.167 0.915 
21 LEU 0.111 0.792 0.244 1.183 0.962 0.991 
26 LEU 0.232 1.004 0.377 0.951 0.697 0.992 
40 LEU 0.144 1.590 0.869 1.575 1.887 1.158 
41 LEU 0.287 1.080 0.485 0.933 1.070 1.071 
42 LEU 0.254 0.871 0.434 1.234 0.867 0.954 






















1 CTRL 0.199 0.553 0.009 0.702 0.284 0.331 
6 CTRL 0.277 0.337 0.009 1.097 0.420 0.407 
11 CTRL 0.295 0.167 0.008 0.684 0.210 0.570 
13 CTRL 0.130 0.490 0.012 1.475 0.467 0.581 
18 CTRL 0.108 0.469 0.007 1.375 0.766 0.809 
23 CTRL 0.096 0.133 0.013 0.662 0.845 0.538 
44 CTRL 0.105 0.381 0.021 0.608 0.723 0.680 
2 WP 0.207 0.335 0.008 0.744 0.560 0.555 
7 WP 0.199 0.286 0.008 1.101 0.915 0.402 
12 WP 0.280 0.387 0.012 0.586 0.839 0.686 
17 WP 0.088 0.573 0.013 0.712 0.392 0.415 
22 WP 0.150 0.362 0.006 0.694 0.447 0.735 
27 WP 0.097 0.719 0.006 0.709 0.392 0.547 
32 HMB 0.197 0.742 0.030 0.780 1.852 0.457 
33 HMB 0.361 0.673 0.034 1.100 2.169 0.500 
34 HMB 0.144 0.433 0.035 0.970 0.825 0.636 
35 HMB 0.190 0.598 0.041 0.710 1.066 0.663 
36 HMB 0.170 0.647 0.021 0.650 2.595 0.672 
37 HMB 0.162 0.558 0.025 0.890 1.259 0.680 
39 HMB 0.171 0.393 0.031 0.770 1.467 0.630 
16 LEU 0.132 0.828 0.028 2.188 0.598 0.575 
21 LEU 0.149 0.603 0.059 0.820 1.034 0.417 
26 LEU 0.147 0.556 0.017 1.362 0.454 0.699 
40 LEU 0.160 0.626 0.190 1.190 0.983 0.621 
41 LEU 0.223 0.479 0.074 1.064 0.982 0.817 
42 LEU 0.222 0.737 0.151 1.205 0.769 0.914 
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